Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21355620 | 0.88 | GRM2 (0.55) | GRM2KLKB1TAS2R8MEN1KMT2A | |
| SCHEMBL21355988 | 0.85 | KLKB1 (0.52) | GRM2KLKB1TAS2R8MEN1KMT2A | |
| SCHEMBL21354786 | 0.81 | KLKB1 (0.58) | GRM2KLKB1MEN1KMT2ATP53 | |
| SCHEMBL29117303 | 0.78 | GRM2 (0.61) | GRM2KLKB1TP53HTTLMNA | |
| SCHEMBL17895755 | 0.78 | L3MBTL1 (0.60) | GRM2KLKB1MEN1KMT2ATP53 | |
| SCHEMBL3765456 | 0.78 | KLKB1 (0.53) | KLKB1POLB | |
| SCHEMBL18794996 | 0.78 | GRM2 (0.53) | GRM2KLKB1MEN1KMT2ATP53 | |
| SCHEMBL4785951 | 0.76 | HSD17B10 (0.59) | GRM2KLKB1TAS2R8MEN1KMT2A | |
| SCHEMBL30736811 | 0.75 | KDM4E (0.51) | GRM2KLKB1MEN1KMT2ATP53 | |
| SCHEMBL1909605 | 0.74 | KLKB1 (0.61) | GRM2KLKB1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | GRM2 4841/4885KLKB1 1/4885TAS2R8 3861/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | GRM2 4841/4885KLKB1 1/4885TAS2R8 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.